Entera Bio Ltd. ROIC

ROIC of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROIC growth rates and interactive chart. Return on invested capital (ROIC) is a calculation used to assess a company's efficiency at allocating the capital under its control to profitable investments. Calculated as Net Operating Profit After Tax or EBIT*(1-tax rate) divided by average invested capital. Invested capital is calculated as equity plus long-term and short-term debt minus cash and short-term investments. ROIC is often compared to the Weighted average cost of capital (WACC). If it's above it, it is said the company is creating value, if it's below it's destroying it. A company with after tax operating profit of $10 million and invested capital of $50 million will have a ROIC of 20%.


Highlights and Quick Summary

  • Annual ROIC for 2019 was 0.0% (a NaN% decrease from previous year)
  • Annual ROIC for 2018 was 0.0% (a NaN% decrease from previous year)
  • Twelve month ROIC ending June 29, 2020 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing ROIC decreased by NaN% year-over-year
Trailing ROIC for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROIC of Entera Bio Ltd.

Most recent ROICof ENTX including historical data for past 10 years.

Interactive Chart of ROIC of Entera Bio Ltd.

Entera Bio Ltd. ROIC for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 0.0%
2018 0.0%
2017 0.0%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.